185954-27-2|Tofimilast|9-Cyclopentyl-7-ethyl-3-(thiophen-2-yl)-6,9-dihydro-5H-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-a)pyridine|-范德生物科技公司

Tofimilast

NMR下载 COA and HPLC MSDS下载
names：
9-Cyclopentyl-7-ethyl-3-(thiophen-2-yl)-6,9-dihydro-5H-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-a)pyridine
CAS号：
185954-27-2
MDL Number：
MF(分子式)： C18H21N5S MW(分子量)： 339.461
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	9-Cyclopentyl-7-ethyl-3-(thiophen-2-yl)-6,9-dihydro-5H-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-a)pyridine
英文别名	Tofimilast; CP-325366; CP 325366; CP325366; CP-325,366; CP 325,366; CP325,366.
CAS号	185954-27-2
Inchi	InChI=1S/C18H21N5S/c1-2-14-13-9-10-22-17(15-8-5-11-24-15)19-20-18(22)16(13)23(21-14)12-6-3-4-7-12/h5,8,11-12H,2-4,6-7,9-10H2,1H3
InchiKey	DHCOPPHTVOXDKU-UHFFFAOYSA-N
分子式 Formula	C18H21N5S
分子量 Molecular Weight	339.461
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Tofimilast(CAS:185954-27-2):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Tofimilast, also known as CP-325366, is a PDE4 inhibitor potentially for the treatment of asthma and chronic obstructive pulmonary disease.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Jaffari S, Forbes B, Collins E, Barlow DJ, Martin GP, Murnane D. Rapidcharacterisation of the inherent dispersibility of respirable powders using drydispersion laser diffraction. Int J Pharm. 2013 Apr 15;447(1-2):124-3[1]doi:10.1016/j.ijpharm.2013.02.034. PubMed PMID: 23434542; PubMed Central PMCID:PMC3636537.

[2]Tralau-Stewart CJ, Williamson RA, Nials AT, Gascoigne M, Dawson J, Hart GJ,Angell AD, Solanke YE, Lucas FS, Wiseman J, Ward P, Ranshaw LE, Knowles RG.GSK256066, an exceptionally high-affinity and selective inhibitor ofphosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic,and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54. doi:10.1124/jpet.110.173690. PubMed PMID: 21205923.

[3] Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors berealized: guarded optimism or wishful thinking? Br J Pharmacol. 2008Oct;155(3):288-90. doi: 10.1038/bjp.2008.297. PubMed PMID: 18660832; PubMedCentral PMCID: PMC2567889.

[4] Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find ExpClin Pharmacol. 2007 Sep;29(7):467-509. PubMed PMID: 17982511.

[5] Duplantier AJ, Bachert EL, Cheng JB, Cohan VL, Jenkinson TH, Kraus KG,McKechney MW, Pillar JD, Watson JW. SAR of a series of5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potentinhibitors of human eosinophil phosphodiesterase. J Med Chem. 2007 Jan25;50(2):344-9. PubMed PMID: 17228876.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开